• Subscribe
  • Advertise
  • Contact Us
June 16, 2025
Pharma News HQ


  • Home
  • News
  • Clinical Trials
  • Drug Development
  • Manufacturing
  • Packaging and Labeling
  • Cold Chain
  • Diseases
  • Technology
  • Press Feed
    • Articles
    • Press Releases
  • Events
Top Headlines
  • [ February 14, 2023 ] Sun Pharma recalls over 34k bottles of generic drug in US due to manufacturing issues Manufacturing
  • [ February 14, 2023 ] Genenta Science signs manufacturing deal with AGC Biologics Manufacturing
  • [ February 14, 2023 ] Vial and Egnyte announce partnership for eTMF solution integration Clinical Trials
  • [ February 14, 2023 ] SOPHiA GENETICS and AstraZeneca partner for oncology drugs development Drug Development
  • [ February 14, 2023 ] FDA suggests ways to curb constraints with rare disease gene therapy trials Clinical Trials
Home2018April

Month: April 2018

News

FDA declines proposed Rituxan, Herceptin biosimilars from Celltrion

April 6, 2018 Pharma News HQ 0

The US Food and Drug Administration has rejected Celltrion’s submissions for biosimilars to Roche drugs Rituxan and Herceptin. According to media reports, the company received complete response letters for Herzuma (trastuzumab; CT-P6) and Truxima (rituximab; […]

News

NICE denies multiple sclerosis star Ocrevus on price, thwarting Roche yet again

April 6, 2018 Pharma News HQ 0

The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s multiple sclerosis therapy Ocrevus. The Institute’s appraisal relates to the drug’s use for treating relapsing forms of multiple sclerosis in […]

Diseases

Novo Nordisk licenses rights to EpiDestiny’s investigational sickle cell disease therapy EPI01

April 6, 2018 Pharma News HQ 0

Danish drugmaker Novo Nordisk has bought a global licence for EpiDestiny’s sickle cell disease (SCD) programme, EPI01. EPI01 is a novel, orally available, disease-modifying therapy, comprised of a fixed-dose formulation of a DNA methyl-transferase enzyme […]

Clinical Trials

CYRAMZA Phase 3 REACH-2 Study Meets Primary Endpoint

April 5, 2018 Pharma News HQ 0

Eli Lilly’ liver cancer treatment Cyramza (ramucirumab) has met its primary endpoint of overall survival (OS) and the secondary endpoint of progression-free survival (PFS) in the phase 3 Reach-2 study. The company has revealed the […]

News

Pfizer and Allogene Therapeutics Enter into Asset Contribution Agreement for Pfizer’s Allogeneic CAR T Immuno-oncology Portfolio

April 4, 2018 Pharma News HQ 0

Pfizer has signed an asset contribution agreement with Allogene Therapeutics for its Allogeneic CAR T immuno-oncology portfolio. Pfizer views this agreement as an attractive opportunity to support the continued development of allogeneic CAR T therapy […]

Posts pagination

« 1 … 9 10 11 12 »



















  • Sun Pharma recalls over 34k bottles of generic drug in US due to manufacturing issues

    February 14, 2023 0
  • Genenta Science signs manufacturing deal with AGC Biologics

    February 14, 2023 0
  • Vial and Egnyte announce partnership for eTMF solution integration

    February 14, 2023 0
  • SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

    February 14, 2023 0
  • FDA suggests ways to curb constraints with rare disease gene therapy trials

    February 14, 2023 0
Pharma News HQ

Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.

 

About Us

 

Subscribe

 

Contact US

Latest Post
  • Sun Pharma recalls over 34k bottles of generic drug in US due to manufacturing issues

    February 14, 2023 0
  • Genenta Science signs manufacturing deal with AGC Biologics

    February 14, 2023 0
  • Vial and Egnyte announce partnership for eTMF solution integration

    February 14, 2023 0
  • SOPHiA GENETICS and AstraZeneca partner for oncology drugs development

    February 14, 2023 0
  • FDA suggests ways to curb constraints with rare disease gene therapy trials

    February 14, 2023 0